News
KPTI
9.77
-3.12%
-0.32
Weekly Report: what happened at KPTI last week (0622-0626)?
Weekly Report · 1d ago
Weekly Report: what happened at KPTI last week (0615-0619)?
Weekly Report · 06/22 09:24
Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell
Seeking Alpha · 06/18 19:53
Analysts Are Bullish on These Healthcare Stocks: BioAge Labs, Inc. (BIOA), Karyopharm Therapeutics (KPTI)
TipRanks · 06/17 13:30
Weekly Report: what happened at KPTI last week (0608-0612)?
Weekly Report · 06/15 09:24
Karyopharm posts Phase 3 SENTRY trial presentation on selinexor plus ruxolitinib in myelofibrosis
PUBT · 06/14 08:14
Karyopharm posts endometrial cancer treatment landscape presentation
PUBT · 06/08 16:04
Weekly Report: what happened at KPTI last week (0601-0605)?
Weekly Report · 06/08 09:23
Karyopharm joins Cantor-hosted webcast featuring endometrial cancer KOL Robert Coleman
PUBT · 06/03 20:15
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
PR Newswire · 06/03 20:15
Karyopharm says Phase 3 SENTRY trial selected for presentation at EHA 2026
TipRanks · 06/02 16:02
Karyopharm posts ASCO 2026 SENTRY trial presentation on selinexor plus ruxolitinib in myelofibrosis
PUBT · 06/02 15:20
Karyopharm’s selinexor combination shows efficacy in myelofibrosis
TipRanks · 06/02 14:47
Karyopharm Therapeutics Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis Accepted For Late-Breaking Oral Presentation At EHA 2026
Benzinga · 06/02 14:10
Karyopharm says Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis wins late-breaking EHA oral slot
PUBT · 06/02 14:03
KARYOPHARM'S PHASE 3 SENTRY TRIAL OF SELINEXOR PLUS RUXOLITINIB IN MYELOFIBROSIS SELECTED FOR LATE-BREAKING ORAL PRESENTATION AT EHA 2026
Reuters · 06/02 14:03
Karyopharm Therapeutics To Present Results Of Phase 3 SENTRY Trial In Late-Breaking Oral Presentation Titled: Selinexor Plus Ruxolitinib In JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial At 2026 ASCO Annual Meeting
Benzinga · 06/02 13:03
Karyopharm says Phase 3 SENTRY trial shows selinexor-ruxolitinib combo lifts SVR35 in myelofibrosis
PUBT · 06/02 13:00
Karyopharm grants 1,200 RSUs to newly hired employee under inducement plan
PUBT · 06/01 20:07
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire · 06/01 20:05
More
Webull provides a variety of real-time KPTI stock news. You can receive the latest news about Karyopharm Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.